Impact of microablative fractional radiofrequency on the vaginal health, microbiota, and cellularity of postmenopausal women

OBJECTIVES: We aimed to evaluate the effectiveness of microablative fractional radiofrequency (MAFRF) in the non-hormonal treatment of genitourinary syndrome of menopause. METHODS: We examined the cases of 55 postmenopausal women before and after treatment with regard to their vaginal health index (VHI), vaginal microbiota, vaginal pH, and cell maturation. Three applications of MAFRF were performed in the vagina/vaginal introitus. During the treatment, six vaginal smears were obtained and stained with the Papanicolaou stain for determining the degree of cell maturation and with Gram stain for classification of vaginal flora, as per the criteria of Spiegel and Amsel. For vaginal pH determination, pH indicator strips were applied against the vaginal wall. Statistical analysis was performed using SPSS for Windows (version 17.0). Data were reported as mean±standard deviation. The differences were analyzed using the statistical method of generalized estimation equations with autoregressive correlation structure “1” and robust standard errors. RESULTS: The mean age was 59.8±4.2 years, and the mean time of menopause was 15.4±4.5 years. After treatment, there was an increase in the percentage of Lactobacillus spp. (p<0.001). Consequently, there was a progressive decrease in vaginal pH during the treatment (p<0.001). Regarding cell maturation, there was a decrease in the percentage of parabasal cells (p=0.001) and an increase in the rate of superficial cells (p<0.001). Additionally, there was an improvement in the VHI index. The mean VHI values before and after treatment were 13.2±5.6 and 22.5±3.7, respectively (p<0.001). CONCLUSION: MAFRF treatment is well tolerated and leads to improvement in the vaginal microenvironment.

[1]  S. Wozniak,et al.  Genitourinary syndrome of menopause treatment using lasers and temperature-controlled radiofrequency , 2018, Przeglad menopauzalny = Menopause review.

[2]  F. Riva,et al.  Early Regenerative Modifications of Human Postmenopausal Atrophic Vaginal Mucosa Following Fractional CO2 Laser Treatment , 2018, Open access Macedonian journal of medical sciences.

[3]  Márcia Farina Kamilos,et al.  New therapeutic option in genitourinary syndrome of menopause: pilot study using microablative fractional radiofrequency , 2017, Einstein.

[4]  Robert D Moore,et al.  Transcutaneous Temperature Controlled Radiofrequency ( TTCRF ) for the Treatment of Menopausal Vaginal / Genitourinary Symptoms-1-# 772 , 2022 .

[5]  M. Karram,et al.  An assessment of the safety and efficacy of a fractional CO2 laser system for the treatment of vulvovaginal atrophy , 2016, Menopause.

[6]  M. Falagas,et al.  The effect of microablative fractional CO2 laser on vaginal flora of postmenopausal women , 2016, Climacteric : the journal of the International Menopause Society.

[7]  F. Vicariotto,et al.  Technological evolution in the radiofrequency treatment of vaginal laxity and menopausal vulvo-vaginal atrophy and other genitourinary symptoms: first experiences with a novel dynamic quadripolar device. , 2016, Minerva ginecologica.

[8]  S. Caruso,et al.  Quality of life and sexual function of naturally postmenopausal women on an ultralow-concentration estriol vaginal gel , 2016, Menopause.

[9]  N. Biglia,et al.  Genitourinary Syndrome of Menopause in Breast Cancer Survivors: Are We Facing New and Safe Hopes? , 2015, Clinical breast cancer.

[10]  D. Portman,et al.  Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and The North American Menopause Society , 2014, Climacteric : the journal of the International Menopause Society.

[11]  S. Ferrero,et al.  A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study , 2014, Climacteric : the journal of the International Menopause Society.

[12]  F. Marotta,et al.  Microscopic and ultrastructural modifications of postmenopausal atrophic vaginal mucosa after fractional carbon dioxide laser treatment , 2014, Lasers in Medical Science.

[13]  M. Martens,et al.  Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society , 2013, Menopause.

[14]  S. Kingsberg,et al.  Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. , 2013, The journal of sexual medicine.

[15]  U. Jaisamrarn,et al.  Ultra-low-dose estriol and lactobacilli in the local treatment of postmenopausal vaginal atrophy , 2013, Climacteric : the journal of the International Menopause Society.

[16]  A. Cano,et al.  The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: results from a pivotal phase III study , 2012, Menopause.

[17]  S. Davis Understanding female sexual function. , 2009, Menopause.

[18]  C. Labrie,et al.  Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women , 2009, Menopause.

[19]  X. Albert,et al.  Oestrogens for Preventing Recurrent Urinary Tract Infection in Postmenopausal Women , 2008, Obstetrics and gynecology.

[20]  G. Bachmann,et al.  Diagnosis and treatment of atrophic vaginitis. , 2000, American family physician.

[21]  K. Holmes,et al.  Diagnosis of bacterial vaginosis by direct gram stain of vaginal fluid , 1983, Journal of clinical microbiology.